Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to -$65.0 million.

  • Praxis Precision Medicines' Free Cash Flow fell 13654.18% to -$65.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$228.9 million, marking a year-over-year decrease of 13008.06%. This contributed to the annual value of -$131.8 million for FY2024, which is 1850.14% down from last year.
  • Praxis Precision Medicines' Free Cash Flow amounted to -$65.0 million in Q3 2025, which was down 13654.18% from -$54.7 million recorded in Q2 2025.
  • Praxis Precision Medicines' 5-year Free Cash Flow high stood at -$20.9 million for Q1 2024, and its period low was -$65.0 million during Q3 2025.
  • In the last 4 years, Praxis Precision Medicines' Free Cash Flow had a median value of -$32.8 million in 2023 and averaged -$40.1 million.
  • As far as peak fluctuations go, Praxis Precision Medicines' Free Cash Flow surged by 4825.86% in 2023, and later plummeted by 15446.61% in 2025.
  • Over the past 4 years, Praxis Precision Medicines' Free Cash Flow (Quarter) stood at -$28.8 million in 2022, then rose by 17.17% to -$23.9 million in 2023, then crashed by 135.2% to -$56.1 million in 2024, then fell by 15.91% to -$65.0 million in 2025.
  • Its Free Cash Flow stands at -$65.0 million for Q3 2025, versus -$54.7 million for Q2 2025 and -$53.1 million for Q1 2025.